<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.48.0">
<page number="1" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="0" size="10" family="Times" color="#231f20"/>
	<fontspec id="1" size="16" family="Times" color="#231f20"/>
	<fontspec id="2" size="14" family="Times" color="#231f20"/>
	<fontspec id="3" size="13" family="Times" color="#231f20"/>
	<fontspec id="4" size="14" family="Times" color="#231f20"/>
	<fontspec id="5" size="22" family="Times" color="#231f20"/>
	<fontspec id="6" size="25" family="Times" color="#231f20"/>
	<fontspec id="7" size="7" family="Times" color="#231f20"/>
	<fontspec id="8" size="14" family="Times" color="#231f20"/>
<text top="108" left="106" width="210" height="12" font="0">Archives of the Balkan Medical Union</text>
<text top="122" left="106" width="226" height="12" font="0">Copyright © 2019 Balkan Medical Union</text>
<text top="108" left="635" width="151" height="12" font="0">vol. 54, no. 2, pp. 384-390</text>
<text top="122" left="728" width="59" height="12" font="0">June 2019</text>
<text top="599" left="457" width="12" height="18" font="1">R</text>
<text top="603" left="469" width="43" height="13" font="0">ÉSUMÉ</text>
<text top="634" left="457" width="330" height="19" font="2"><b>Caractéristiques de l’évolution de la pneumonie ac-</b></text>
<text top="653" left="457" width="329" height="19" font="2"><b>quise communautaire chez un enfant atteint du syn-</b></text>
<text top="672" left="457" width="175" height="19" font="2"><b>drome de Kasabach-Merritt</b></text>
<text top="713" left="457" width="97" height="16" font="3">Introduction.  </text>
<text top="709" left="556" width="234" height="19" font="4">Le syndrome de Kasabach-Merritt est </text>
<text top="728" left="457" width="334" height="19" font="4">un processus pathologique rare et grave qui survient </text>
<text top="747" left="457" width="334" height="19" font="4">chez l’enfant en présence d’hémangiomes de grande </text>
<text top="766" left="457" width="333" height="19" font="4">taille et accompagné de troubles de la coagulation. </text>
<text top="784" left="457" width="329" height="19" font="4">Cette pathologie est souvent compliquée par le dé-</text>
<text top="803" left="457" width="334" height="19" font="4">veloppement de saignements sévères, de thromboses </text>
<text top="822" left="457" width="329" height="19" font="4">locales, d’anémie et de dysfonctionnements des or-</text>
<text top="841" left="457" width="334" height="19" font="4">ganes vitaux. Il est logique que cet état pathologique </text>
<text top="859" left="457" width="333" height="19" font="4">puisse compliquer l’évolution de nombreuses maladies </text>
<text top="878" left="457" width="329" height="19" font="4">somatiques chez l’enfant, y compris la pneumonie ex-</text>
<text top="897" left="457" width="333" height="19" font="4">tra-hospitalière, principalement en raison de troubles </text>
<text top="916" left="457" width="139" height="19" font="4">du caillement sanguin.</text>
<text top="938" left="457" width="124" height="16" font="3">Rapport du cas. </text>
<text top="934" left="582" width="210" height="19" font="4">L’objet de notre étude était un </text>
<text top="953" left="457" width="334" height="19" font="4">enfant de 4,5 mois souffrant d’une combinaison de </text>
<text top="972" left="457" width="335" height="19" font="4">maladies comme l’hémangiome capillaire du côté </text>
<text top="991" left="457" width="334" height="19" font="4">droit de la poitrine, compliqué par le développement </text>
<text top="1009" left="457" width="333" height="19" font="4">du syndrome de Kasabach-Merritt et la pneumonie </text>
<text top="599" left="106" width="12" height="18" font="1">A</text>
<text top="603" left="118" width="55" height="13" font="0">BSTRACT</text>
<text top="638" left="106" width="94" height="16" font="3">Introduction. </text>
<text top="634" left="203" width="237" height="19" font="4">The Kasabach-Merritt syndrome is a </text>
<text top="653" left="106" width="333" height="19" font="4">rare and severe disease that occurs in children in the </text>
<text top="672" left="106" width="334" height="19" font="4">presence of a large-sized hemangioma, accompanied </text>
<text top="691" left="106" width="333" height="19" font="4">by coagulation disorders. This disease complicates the </text>
<text top="709" left="106" width="333" height="19" font="4">course of many somatic diseases in children, including </text>
<text top="728" left="106" width="334" height="19" font="4">community-acquired pneumonia, due to the clotting </text>
<text top="747" left="106" width="54" height="19" font="4">disorder.</text>
<text top="770" left="106" width="133" height="16" font="3">Case presentation. </text>
<text top="766" left="242" width="198" height="19" font="4">A case of a 4.5-month-old child </text>
<text top="784" left="106" width="334" height="19" font="4">with a combination of capillary hemangioma of the </text>
<text top="803" left="106" width="333" height="19" font="4">dextral chest surface, complicated by Kasabach-Merritt </text>
<text top="822" left="106" width="334" height="19" font="4">syndrome, and community-acquired right-sided focal </text>
<text top="841" left="106" width="333" height="19" font="4">pneumonia is presented. The possible effect of the </text>
<text top="859" left="106" width="329" height="19" font="4">Kasabach-Merritt syndrome on the course of com-</text>
<text top="878" left="106" width="336" height="19" font="4">munity-acquired pneumonia has been analyzed. </text>
<text top="897" left="106" width="335" height="19" font="4">Additionally, the drugs’ effect on the coagulation </text>
<text top="916" left="106" width="335" height="19" font="4">disorder, the state of hemangioma, and the course </text>
<text top="934" left="106" width="333" height="19" font="4">of community-acquired pneumonia in children have </text>
<text top="953" left="106" width="110" height="19" font="4">been investigated.</text>
<text top="976" left="106" width="89" height="16" font="3">Conclusions. </text>
<text top="972" left="199" width="241" height="19" font="4">Severe coagulation disorders may occur </text>
<text top="991" left="106" width="329" height="19" font="4">in patients with Kasabach-Merritt syndrome and com-</text>
<text top="1009" left="106" width="334" height="19" font="4">munity-acquired pneumonia. Constant monitoring is </text>
<text top="200" left="434" width="353" height="24" font="5">CASE REPORT AND MINI-REVIEW</text>
<text top="311" left="106" width="685" height="27" font="6">FEATURES OF THE COMMUNITY–ACQUIRED PNEUMONIA </text>
<text top="341" left="106" width="623" height="27" font="6">IN A CHILD WITH KASABACH-MERRITT SYNDROME: </text>
<text top="371" left="106" width="398" height="27" font="6">CASE-REPORT AND MINI-REVIEW</text>
<text top="423" left="106" width="155" height="17" font="4">Oksana BOYARCHUK</text>
<text top="422" left="262" width="6" height="10" font="7">1</text>
<text top="423" left="268" width="169" height="17" font="4">, Andrii CHORNOMYDZ</text>
<text top="422" left="437" width="9" height="10" font="7">2 </text>
<text top="423" left="454" width="163" height="17" font="4">, Iryna CHORNOMYDZ</text>
<text top="422" left="616" width="6" height="10" font="7">1</text>
<text top="447" left="106" width="5" height="11" font="7">1</text>
<text top="446" left="111" width="679" height="19" font="4"> Department of Children’s Diseases and Pediatric Surgery, I. Horbachevsky Ternopil State Medical </text>
<text top="465" left="106" width="192" height="19" font="4">University, Ternopil, Ukraine</text>
<text top="485" left="106" width="5" height="11" font="7">2</text>
<text top="484" left="111" width="679" height="19" font="4"> Department of Pharmacology and Clinical Pharmacology, I. Horbachevsky Ternopil State Medical </text>
<text top="503" left="106" width="192" height="19" font="4">University, Ternopil, Ukraine</text>
<text top="521" left="326" width="460" height="19" font="8"><i>Received 3 Febr 2019, Corrections received 23 Apr 2019, Accepted 30 Apr 2019</i></text>
<text top="545" left="549" width="238" height="12" font="0">https://doi.org/10.31688/ABMU.2019.54.2.28</text>
<text top="1079" left="143" width="167" height="13" font="0"> Address for correspondence:  </text>
<text top="1079" left="348" width="114" height="13" font="0"> Andrii CHORNOMYDZ</text>
<text top="1096" left="348" width="398" height="13" font="0">Department of Pharmacology and Clinical Pharmacology, I. Horbachevsky </text>
<text top="1113" left="348" width="274" height="13" font="0">Ternopil State Medical University, Ternopil, Ukraine</text>
<text top="1131" left="348" width="272" height="13" font="0">Address: 1, Maydan Voli, Ternopil, 46001, Ukraine</text>
<text top="1148" left="348" width="182" height="13" font="0">E-mail: chornomydz@tdmu.edu.ua</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="9" size="11" family="Times" color="#231f20"/>
<text top="91" left="552" width="235" height="14" font="9">Archives of the Balkan Medical Union</text>
<text top="1182" left="660" width="42" height="14" font="9">June </text>
<text top="1182" left="693" width="94" height="14" font="9">2019 / 385</text>
<text top="596" left="106" width="5" height="18" font="1">I</text>
<text top="600" left="112" width="85" height="13" font="0">NTRODUCTION</text>
<text top="632" left="136" width="300" height="19" font="4">The vascular tumors are one of the most com-</text>
<text top="651" left="106" width="179" height="19" font="4">mon neoplasms in children</text>
<text top="652" left="285" width="12" height="11" font="7">1,2</text>
<text top="651" left="297" width="139" height="19" font="4">. Despite the skin he-</text>
<text top="671" left="106" width="335" height="19" font="4">mangiomas’ multiplicity and size, their diagnosis </text>
<text top="691" left="106" width="333" height="19" font="4">does not cause significant difficulties, and the benign </text>
<text top="710" left="106" width="228" height="19" font="4">course leads to a favorable prognosis</text>
<text top="711" left="334" width="18" height="11" font="7">1,3,4</text>
<text top="710" left="352" width="4" height="19" font="4">.</text>
<text top="730" left="136" width="300" height="19" font="4">However, in 0.3-1% of hemangiomas cases, com-</text>
<text top="750" left="106" width="335" height="19" font="4">plicating disorders, such as the Kasabach–Merritt </text>
<text top="769" left="106" width="149" height="19" font="4">syndrome (KMS), occur</text>
<text top="770" left="256" width="11" height="11" font="7">5-7</text>
<text top="769" left="266" width="174" height="19" font="4">. This is a rare disease that </text>
<text top="789" left="106" width="329" height="19" font="4">infants may suffer at birth or in later life and is char-</text>
<text top="808" left="106" width="329" height="19" font="4">acterized by hemangioma’s size increasing, coagu-</text>
<text top="828" left="106" width="334" height="19" font="4">lopathy, thrombocytopenia, hemolytic anemia, and </text>
<text top="848" left="106" width="194" height="19" font="4">severe bleeding complications</text>
<text top="848" left="301" width="20" height="11" font="7">3,6-8</text>
<text top="848" left="321" width="120" height="19" font="4">. Approx. 80% of </text>
<text top="867" left="106" width="334" height="19" font="4">Kasabach-Merritt syndrome cases are diagnosed in </text>
<text top="887" left="106" width="134" height="19" font="4">children during the 1</text>
<text top="887" left="240" width="6" height="11" font="7">st</text>
<text top="887" left="246" width="193" height="19" font="4"> year of age, and the registered </text>
<text top="906" left="106" width="213" height="19" font="4">mortality range from 10% to 37%</text>
<text top="907" left="319" width="19" height="11" font="7">5,6,9</text>
<text top="906" left="338" width="4" height="19" font="4">.</text>
<text top="926" left="136" width="304" height="19" font="4">Considering the fact that the Kasabach–Merritt </text>
<text top="946" left="106" width="334" height="19" font="4">syndrome is a life-threatening illness, other diseases </text>
<text top="965" left="106" width="333" height="19" font="4">that may appear in patients with this syndrome have </text>
<text top="985" left="106" width="333" height="19" font="4">certain evolution and therapeutic particularities. On </text>
<text top="1005" left="106" width="333" height="19" font="4">the one hand, the development of thrombocytopenia </text>
<text top="1024" left="106" width="333" height="19" font="4">and hemolytic anemia complicates the course of many </text>
<text top="1044" left="106" width="334" height="19" font="4">diseases, including pneumonia, on the other hand, </text>
<text top="1063" left="106" width="334" height="19" font="4">acute inflammatory diseases and prescribed drugs </text>
<text top="1083" left="106" width="329" height="19" font="4">can adversely impact on the course of the Kasabach–</text>
<text top="1103" left="106" width="330" height="19" font="4">Merritt syndrome. Such a rare combination of com-</text>
<text top="1122" left="106" width="334" height="19" font="4">munity-acquired pneumonia and Kasabach–Merritt </text>
<text top="1142" left="106" width="328" height="19" font="4">syndrome is a serious challenge for any pediatrician.</text>
<text top="596" left="457" width="12" height="18" font="1">C</text>
<text top="600" left="469" width="23" height="13" font="0">ASE</text>
<text top="596" left="492" width="5" height="18" font="1"> </text>
<text top="600" left="498" width="89" height="13" font="0">PRESENTATION</text>
<text top="631" left="487" width="306" height="19" font="4">We report the case of a 4.5-month-old girl, </text>
<text top="650" left="457" width="334" height="19" font="4">who was admitted to Ternopil Regional Children’s </text>
<text top="669" left="457" width="329" height="19" font="4">Hospital, Ukraine, complaining of wet cough, de-</text>
<text top="688" left="457" width="334" height="19" font="4">creased appetite, body temperature up to 37.2° C. </text>
<text top="707" left="457" width="335" height="19" font="4">The history showed that the child had concretion </text>
<text top="726" left="457" width="329" height="19" font="4">and soft-tissue swelling in the area of the dextral lat-</text>
<text top="745" left="457" width="334" height="19" font="4">eral surface of the breast since birth. At the age of 2 </text>
<text top="764" left="457" width="334" height="19" font="4">months, in the center of the concretion, which was </text>
<text top="782" left="457" width="334" height="19" font="4">gradually increasing and reached 10x8 cm, the skin </text>
<text top="801" left="457" width="333" height="19" font="4">turned into blue-cherry color without sharp contours </text>
<text top="820" left="457" width="333" height="19" font="4">and 2 cm in diameter. After specialists’ examination </text>
<text top="839" left="457" width="334" height="19" font="4">and follow-up examination, a capillary hemangioma </text>
<text top="858" left="457" width="329" height="19" font="4">of the dextral lateral surface of the breast was diag-</text>
<text top="877" left="457" width="333" height="19" font="4">nosed. Three days after, an altered general condition </text>
<text top="896" left="457" width="333" height="19" font="4">was noted: subfebrility, restlessness, appetite loss and </text>
<text top="915" left="457" width="334" height="19" font="4">general weakness appeared, the hematoma covered </text>
<text top="934" left="457" width="335" height="19" font="4">most dextral half of the trunk and dextral lower </text>
<text top="953" left="457" width="335" height="19" font="4">limb. Kasabach–Merritt syndrome was diagnosed: </text>
<text top="972" left="457" width="329" height="19" font="4">cavernous hemangioma of the dextral chest wall; se-</text>
<text top="991" left="457" width="334" height="19" font="4">vere thrombocytopenia; moderate post-hemorrhagic </text>
<text top="1009" left="457" width="335" height="19" font="4">anemia; hemorrhagic syndrome: hematoma of the </text>
<text top="1028" left="457" width="334" height="19" font="4">dextral half of the trunk, subcutaneous hematoma </text>
<text top="1047" left="457" width="334" height="19" font="4">of the extremities, dextral hemothorax (drainage of </text>
<text top="1066" left="457" width="329" height="19" font="4">the dextral pleural cavity). The packed red cell trans-</text>
<text top="1085" left="457" width="334" height="19" font="4">fusion, fresh frozen plasma transfusion and platelet </text>
<text top="1104" left="457" width="334" height="19" font="4">transfusion, anticoagulation reversal, antimicrobial </text>
<text top="1123" left="457" width="335" height="19" font="4">therapy, and glucocorticosteroids were prescribed. </text>
<text top="1142" left="457" width="336" height="19" font="4">As a result of the treatment, the general status </text>
<text top="126" left="457" width="329" height="19" font="4">extra-hospitalière. Le rapport clinique présenté ana-</text>
<text top="145" left="457" width="334" height="19" font="4">lyse les mécanismes possibles de l’effet du syndrome </text>
<text top="164" left="457" width="330" height="19" font="4">de Kasabach-Merritt sur le cours de la pneumonie ex-</text>
<text top="182" left="457" width="334" height="19" font="4">tra-hospitalière par l’exemple du dossier clinique de </text>
<text top="201" left="457" width="334" height="19" font="4">l’enfant que nous avons traité. Nous avons analysé les </text>
<text top="220" left="457" width="333" height="19" font="4">particularités du traitement du point de vue de l’effet </text>
<text top="239" left="457" width="334" height="19" font="4">des médicaments sur les troubles de la coagulation, </text>
<text top="257" left="457" width="329" height="19" font="4">l’état des hémangiomes et le déroulement de la pneu-</text>
<text top="276" left="457" width="232" height="19" font="4">monie extra-hospitalière chez l’enfant.</text>
<text top="299" left="457" width="88" height="16" font="3">Conclusions. </text>
<text top="295" left="548" width="242" height="19" font="4">Quant le syndrome de Kasabach-Merritt </text>
<text top="314" left="457" width="333" height="19" font="4">est associé à une pneumonie d’origine communautaire, </text>
<text top="332" left="457" width="329" height="19" font="4">il est nécessaire de considérer le développement pos-</text>
<text top="351" left="457" width="334" height="19" font="4">sible de complications hémorragiques graves. Pendant </text>
<text top="370" left="457" width="335" height="19" font="4">le séjour des patients à l’hôpital, une surveillance </text>
<text top="389" left="457" width="333" height="19" font="4">constante du système sanguin congestif est nécessaire. </text>
<text top="407" left="457" width="333" height="19" font="4">Le traitement de cette association de maladies doit être </text>
<text top="426" left="457" width="329" height="19" font="4">effectué en tenant compte de la capacité des médica-</text>
<text top="445" left="457" width="333" height="19" font="4">ments à influencer à la fois le système hémostatique et </text>
<text top="464" left="457" width="201" height="19" font="4">la progression des hémangiomes.</text>
<text top="505" left="457" width="78" height="16" font="3">Mots-clés: </text>
<text top="501" left="538" width="249" height="19" font="4">syndrome de Kasabach-Merritt, héman-</text>
<text top="520" left="457" width="334" height="19" font="4">giome, pneumonie extra-hospitalière, enfants, trouble </text>
<text top="539" left="457" width="139" height="19" font="4">du caillement sanguin.</text>
<text top="126" left="106" width="334" height="19" font="4">essential during hospitalization. Such combination of </text>
<text top="145" left="106" width="334" height="19" font="4">diseases should be treated considering the ability of </text>
<text top="164" left="106" width="333" height="19" font="4">the drugs to influence both the hemostasis system and </text>
<text top="182" left="106" width="252" height="19" font="4">the progression of hemangioma’s growth.</text>
<text top="224" left="106" width="75" height="16" font="3">Keywords: </text>
<text top="220" left="185" width="251" height="19" font="4">Kasabach-Merritt syndrome, hemangio-</text>
<text top="239" left="106" width="329" height="19" font="4">ma, community-acquired pneumonia, children, clot-</text>
<text top="257" left="106" width="82" height="19" font="4">ting disorder.</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="10" size="11" family="Times" color="#231f20"/>
<image top="126" left="106" width="330" height="450" src="/export/freefileconvert/7625_d97baffa68d8bf2caa4267938c1c0d989883edcfee0a355784aee2dfcca71129-3_1.png"/>
<text top="91" left="106" width="667" height="14" font="9">Features of the community–acquired pneumonia in a child with kasabach-merritt syndrome… – BOYARCHUK et al</text>
<text top="1182" left="106" width="143" height="14" font="9">386  /  vol. 54, no. 2</text>
<text top="655" left="106" width="334" height="19" font="4">improvement was noticed and the child was referred </text>
<text top="675" left="106" width="333" height="19" font="4">to the Republican Center on Pediatric Hematology </text>
<text top="694" left="106" width="334" height="19" font="4">«Okhmatdyt», Ukraine. In the clinic, the diagnosis </text>
<text top="714" left="106" width="334" height="19" font="4">has been confirmed and it has been established that </text>
<text top="733" left="106" width="330" height="19" font="4">the surgical removal of the hemangioma is impossi-</text>
<text top="752" left="106" width="329" height="19" font="4">ble, due to the large volume of neoplasm and ger-</text>
<text top="772" left="106" width="334" height="19" font="4">mination in surrounding tissues. The conservative </text>
<text top="791" left="106" width="334" height="19" font="4">treatment with corticosteroids and propranolol was </text>
<text top="811" left="106" width="335" height="19" font="4">assigned. A post-discharge improvement in child’s </text>
<text top="830" left="106" width="334" height="19" font="4">health was noticed, the tumor marginally decreased </text>
<text top="850" left="106" width="329" height="19" font="4">in size, the signs of hemorrhagic syndrome subsided.</text>
<text top="869" left="136" width="305" height="19" font="4">Five days before the current admission to the </text>
<text top="889" left="106" width="334" height="19" font="4">hospital, the child’s condition has deteriorated, and </text>
<text top="908" left="106" width="334" height="19" font="4">the above-mentioned complaints have appeared. On </text>
<text top="928" left="106" width="334" height="19" font="4">physical examination, the general child’s condition </text>
<text top="947" left="106" width="329" height="19" font="4">was moderately severe. She had visible mucous mem-</text>
<text top="967" left="106" width="333" height="19" font="4">branes of pale pink color, infiltration of the skin with </text>
<text top="986" left="106" width="333" height="19" font="4">a red-blue color and poorly demarcated round shape, </text>
<text top="1006" left="106" width="329" height="19" font="4">7 cm in diameter, was noted in the area of the dex-</text>
<text top="1025" left="106" width="333" height="19" font="4">tral surface of the chest (Fig. 1). There were petechiae </text>
<text top="1044" left="106" width="334" height="19" font="4">hemorrhages and signs of intradermal hemorrhages </text>
<text top="1064" left="106" width="334" height="19" font="4">around the navel extending over the entire surface </text>
<text top="1083" left="106" width="334" height="19" font="4">of the dextral half of the trunk, with the transition </text>
<text top="1103" left="106" width="335" height="19" font="4">to the back and the anterior abdominal wall. The </text>
<text top="1122" left="106" width="330" height="19" font="4">tumor was elastic, akinetic, with no evidence of in-</text>
<text top="1142" left="106" width="334" height="19" font="4">flammation on palpation. The patient was eupneic, </text>
<text top="126" left="457" width="330" height="19" font="4">with nasal breathing, frequency of respiratory move-</text>
<text top="145" left="457" width="334" height="19" font="4">ments – 42 per minute, dullness on percussion over </text>
<text top="164" left="457" width="329" height="19" font="4">the lungs in the lower sections of the right and be-</text>
<text top="183" left="457" width="329" height="19" font="4">tween the shoulder blade was concluded. By auscul-</text>
<text top="201" left="457" width="334" height="19" font="4">tation – crackles and crepitations were heard on the </text>
<text top="220" left="457" width="334" height="19" font="4">right hemithorax, in the lower sections. The cardiac </text>
<text top="239" left="457" width="334" height="19" font="4">sounds were rhythmic, with a heart rate of 132 beats </text>
<text top="258" left="457" width="334" height="19" font="4">per minute. No pathological findings were detected </text>
<text top="277" left="457" width="334" height="19" font="4">at the abdominal examination. Bowel and bladder </text>
<text top="295" left="457" width="334" height="19" font="4">habits were normal. At chest X-ray examination, a </text>
<text top="314" left="457" width="333" height="19" font="4">consolidation in the basal segments of the right lung </text>
<text top="333" left="457" width="334" height="19" font="4">was observed, with increased pulmonary vascularity. </text>
<text top="352" left="457" width="334" height="19" font="4">Blood tests revealed anemia (hemoglobin 9.0 g/dL), </text>
<text top="371" left="457" width="176" height="19" font="4">thrombocytopenia (118 x 10</text>
<text top="371" left="633" width="5" height="11" font="7">9</text>
<text top="371" left="637" width="155" height="19" font="4">/dL), normal leukocytes </text>
<text top="389" left="457" width="333" height="19" font="4">and no increase in the number of immature forms </text>
<text top="408" left="457" width="335" height="19" font="4">of neutrophilic leukocytes. C-reactive protein – 6 </text>
<text top="427" left="457" width="333" height="19" font="4">mg/dL. The biochemical analysis of blood and urine </text>
<text top="446" left="457" width="333" height="19" font="4">were normal. The ultrasound examination revealed a </text>
<text top="465" left="457" width="334" height="19" font="4">small amount of fluid in the right pleural sinus. The </text>
<text top="483" left="457" width="329" height="19" font="4">child consulted a hematologist, a cardiologist, an on-</text>
<text top="502" left="457" width="333" height="19" font="4">cologist, a thoracic surgeon, and other specialists. She </text>
<text top="521" left="457" width="334" height="19" font="4">was diagnosed with community-acquired right-focal </text>
<text top="540" left="457" width="329" height="19" font="4">pneumonia, and Kasabach–Merritt syndrome: cavern-</text>
<text top="559" left="457" width="330" height="19" font="4">ous hemangioma of the right chest wall, mild throm-</text>
<text top="577" left="457" width="197" height="19" font="4">bocytopenia, moderate anemia.</text>
<text top="596" left="487" width="304" height="19" font="4">Conservative treatment was initiated, including </text>
<text top="615" left="457" width="334" height="19" font="4">antimicrobial therapy (amoxicillin + clavulanic acid </text>
<text top="634" left="457" width="329" height="19" font="4">(daily dose – 40 mg/5 mg per kg) intravenously, ex-</text>
<text top="653" left="457" width="333" height="19" font="4">pectorants (ambroxol, daily dose – 15 mg), oxygen </text>
<text top="671" left="457" width="334" height="19" font="4">therapy, vitamin E 0.5 ml of 10% solution per day, </text>
<text top="690" left="457" width="333" height="19" font="4">aminocaproic acid 5% – 2.5 ml, 4 times a day. During </text>
<text top="709" left="457" width="330" height="19" font="4">follow-up, the amelioration of clinical signs was no-</text>
<text top="728" left="457" width="152" height="19" font="4">ticed, but during the 4</text>
<text top="729" left="609" width="8" height="11" font="7">th</text>
<text top="728" left="618" width="169" height="19" font="4"> day, the platelet level de-</text>
<text top="747" left="457" width="104" height="19" font="4">creased to 98x10</text>
<text top="747" left="561" width="5" height="11" font="7">9</text>
<text top="747" left="565" width="225" height="19" font="4">/dL. Glucocorticoids were added to </text>
<text top="765" left="457" width="333" height="19" font="4">treatment (prednisolone 2.5 mg per kg per day). The </text>
<text top="784" left="457" width="333" height="19" font="4">condition of the child improved, a positive change on </text>
<text top="803" left="457" width="333" height="19" font="4">the X-ray was established, and the level of platelets by </text>
<text top="822" left="457" width="209" height="19" font="4">the end of treatment was 209x10</text>
<text top="823" left="666" width="5" height="11" font="7">9</text>
<text top="822" left="671" width="122" height="19" font="4">/dL. The duration </text>
<text top="841" left="457" width="334" height="19" font="4">of the antibiotic therapy was 10 days, the length of </text>
<text top="860" left="457" width="334" height="19" font="4">hospital stay – 12 days. The child was discharged in </text>
<text top="878" left="457" width="138" height="19" font="4">satisfactory condition.</text>
<text top="918" left="457" width="12" height="18" font="1">D</text>
<text top="922" left="469" width="65" height="13" font="0">ISCUSSION</text>
<text top="953" left="487" width="300" height="19" font="4">The Kasabach-Merritt syndrome was first de-</text>
<text top="972" left="457" width="335" height="19" font="4">scribed by Haig Haiguni Kasabach and Katharine </text>
<text top="991" left="457" width="333" height="19" font="4">Krom Merritt in 1940, when they observed infants </text>
<text top="1010" left="457" width="330" height="19" font="4">with gigantic capillary hemangiomas and thrombo-</text>
<text top="1029" left="457" width="333" height="19" font="4">cytopenic purpura. This is a rather rare pathology </text>
<text top="1047" left="457" width="334" height="19" font="4">and the total number of described cases was toward </text>
<text top="1066" left="457" width="330" height="19" font="4">200. Every major hemangioma doesn’t have to be ac-</text>
<text top="1085" left="457" width="330" height="19" font="4">companied by the development of KMS. The mor-</text>
<text top="1104" left="457" width="333" height="19" font="4">tality rate is less than 10% in cases of skin lesions </text>
<text top="1123" left="457" width="334" height="19" font="4">and reaches 60% in the presence of retroperitoneal </text>
<text top="1141" left="457" width="45" height="19" font="4">tumors</text>
<text top="1142" left="502" width="16" height="11" font="7">8,10</text>
<text top="1141" left="518" width="4" height="19" font="4">.</text>
<text top="584" left="175" width="195" height="15" font="10"><b>Figure 1</b>. Cavernous hemangioma </text>
<text top="601" left="152" width="238" height="15" font="9">of the right half of the chest wall in a child</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1262" width="892">
<image top="126" left="105" width="333" height="411" src="/export/freefileconvert/7625_d97baffa68d8bf2caa4267938c1c0d989883edcfee0a355784aee2dfcca71129-4_1.png"/>
<text top="91" left="552" width="235" height="14" font="9">Archives of the Balkan Medical Union</text>
<text top="1182" left="661" width="42" height="14" font="9">June </text>
<text top="1182" left="693" width="93" height="14" font="9">2019 / 387</text>
<text top="616" left="136" width="303" height="19" font="4">The exact etiology and pathogenesis of the disease </text>
<text top="635" left="106" width="330" height="19" font="4">are unknown, but in some cases, the hereditary pat-</text>
<text top="654" left="106" width="333" height="19" font="4">tern of this pathology has been discovered, autosomal </text>
<text top="672" left="106" width="91" height="19" font="4">dominant type</text>
<text top="673" left="197" width="9" height="11" font="7">11</text>
<text top="672" left="205" width="201" height="19" font="4">, although some papers deny this</text>
<text top="673" left="405" width="9" height="11" font="7">12</text>
<text top="672" left="414" width="4" height="19" font="4">.</text>
<text top="691" left="136" width="300" height="19" font="4">By mechanism, the processes that occur in he-</text>
<text top="710" left="106" width="330" height="19" font="4">mangioma are the chronic form of disseminated in-</text>
<text top="729" left="106" width="329" height="19" font="4">travascular blood coagulation. Blood circulation slow-</text>
<text top="748" left="106" width="333" height="19" font="4">ing, with a large number of microtubes and increased </text>
<text top="766" left="106" width="333" height="19" font="4">use of platelets occurs in a giant hemangioma, which </text>
<text top="785" left="106" width="334" height="19" font="4">has a branched vascular network. The coagulopathy </text>
<text top="804" left="106" width="329" height="19" font="4">occurs preferentially due to the defects in the en-</text>
<text top="823" left="106" width="334" height="19" font="4">dothelium of the vessels inside hemangioma, which </text>
<text top="841" left="106" width="151" height="19" font="4">cause platelet activation</text>
<text top="842" left="257" width="5" height="11" font="7">6</text>
<text top="841" left="262" width="178" height="19" font="4">. In normal conditions, the </text>
<text top="860" left="106" width="334" height="19" font="4">vascular endothelium prevents thrombocytopenia in </text>
<text top="879" left="106" width="68" height="19" font="4">many ways</text>
<text top="880" left="174" width="20" height="11" font="7">13,14</text>
<text top="879" left="194" width="241" height="19" font="4">. The endothelium damage or its dys-</text>
<text top="898" left="106" width="334" height="19" font="4">function is a key factor in platelet activation inside </text>
<text top="916" left="106" width="333" height="19" font="4">hemangioma in the Kasabach-Merritt syndrome. The </text>
<text top="935" left="106" width="334" height="19" font="4">blood flow abnormality inside hemangioma due to </text>
<text top="954" left="106" width="334" height="19" font="4">excessive blood transfusion contributes more to the </text>
<text top="973" left="106" width="115" height="19" font="4">platelets activation</text>
<text top="973" left="220" width="9" height="11" font="7">15</text>
<text top="973" left="230" width="210" height="19" font="4">. As a result, secondary (acquired, </text>
<text top="992" left="106" width="329" height="19" font="4">symptomatic) thrombocytopenia and coagulopa-</text>
<text top="1010" left="106" width="334" height="19" font="4">thy develop, which are associated with an increase </text>
<text top="1029" left="106" width="333" height="19" font="4">in blood loss in hemangiomas. Thrombocytopenia </text>
<text top="1048" left="106" width="330" height="19" font="4">contributes to the reduction of thrombocyte produc-</text>
<text top="1067" left="106" width="334" height="19" font="4">tion, as the functional depletion of reserves occurs, </text>
<text top="1085" left="106" width="333" height="19" font="4">connected with the constant increased destruction of </text>
<text top="1104" left="106" width="154" height="19" font="4">platelets in hemangioma</text>
<text top="1105" left="260" width="20" height="11" font="7">12,16</text>
<text top="1104" left="280" width="4" height="19" font="4">.</text>
<text top="1123" left="136" width="305" height="19" font="4">Sometimes, the diagnosis of Kasabach-Merritt </text>
<text top="1142" left="106" width="337" height="19" font="4">syndrome is not difficult, due to the tumor </text>
<text top="126" left="457" width="334" height="19" font="4">predominant localization on the skin surface, as in </text>
<text top="145" left="457" width="329" height="19" font="4">our case, and the presence of blood clotting disrup-</text>
<text top="164" left="457" width="330" height="19" font="4">tion signs. The disorders which occur due to thrombo-</text>
<text top="183" left="457" width="333" height="19" font="4">cytopenia lead to spontaneous bleeding accompanied </text>
<text top="201" left="457" width="335" height="19" font="4">by ecchymoses, petechiae and hemangioma’s rapid </text>
<text top="220" left="457" width="76" height="19" font="4">size increase</text>
<text top="221" left="533" width="20" height="11" font="7">12,17</text>
<text top="220" left="552" width="239" height="19" font="4">. In case of severe thrombocytopenia, </text>
<text top="239" left="457" width="333" height="19" font="4">the bleeding from the mucous membrane of the nasal </text>
<text top="258" left="457" width="334" height="19" font="4">cavity and the gastrointestinal tract, with subsequent </text>
<text top="277" left="457" width="253" height="19" font="4">development of severe anemia may occur</text>
<text top="277" left="709" width="20" height="11" font="7">12,16</text>
<text top="277" left="729" width="4" height="19" font="4">.</text>
<text top="295" left="487" width="304" height="19" font="4">In the context of the described clinical picture, </text>
<text top="314" left="457" width="334" height="19" font="4">there were also multiple signs of disruption of blood </text>
<text top="333" left="457" width="335" height="19" font="4">coagulation (petechiae and extensive intradermal </text>
<text top="352" left="457" width="333" height="19" font="4">hemorrhages) (Fig. 2). Therefore, in Kasabach-Merritt </text>
<text top="371" left="457" width="329" height="19" font="4">syndrome and another disease (in our case, communi-</text>
<text top="389" left="457" width="334" height="19" font="4">ty-acquired pneumonia), one should be prepared for </text>
<text top="408" left="457" width="330" height="19" font="4">the complications associated with the risk of hemor-</text>
<text top="427" left="457" width="330" height="19" font="4">rhagic syndrome. In case of pneumonia, the develop-</text>
<text top="446" left="457" width="330" height="19" font="4">ment of a severe hemorrhagic process in lungs, in-</text>
<text top="465" left="457" width="334" height="19" font="4">tra-pulmonary haemorrhage, hemothorax and other </text>
<text top="483" left="457" width="333" height="19" font="4">organs hemorrhage (gastrointestinal tract, hematuria, </text>
<text top="502" left="457" width="334" height="19" font="4">etc.) may be encountered. Due to the absence of a </text>
<text top="521" left="457" width="333" height="19" font="4">severe clinical course of pneumonia, our patient did </text>
<text top="540" left="457" width="181" height="19" font="4">not have such complications.</text>
<text top="559" left="487" width="305" height="19" font="4">Nevertheless, an important issue is the choice </text>
<text top="578" left="457" width="334" height="19" font="4">of the most appropriate treatment in the presence of </text>
<text top="596" left="457" width="330" height="19" font="4">such combination of pathological processes. The dif-</text>
<text top="615" left="457" width="333" height="19" font="4">ficulties in choosing the right treatment are based on </text>
<text top="634" left="457" width="157" height="19" font="4">several important points:</text>
<text top="653" left="487" width="304" height="19" font="4">1. Can the drugs used for the Kasabach-Merritt </text>
<text top="672" left="457" width="330" height="19" font="4">syndrome treatment (or gigantic capillary hemangio-</text>
<text top="690" left="457" width="232" height="19" font="4">mas) increase the risk of pneumonia?</text>
<text top="709" left="487" width="304" height="19" font="4">2. Can the drugs used for the Kasabach-Merritt </text>
<text top="728" left="457" width="330" height="19" font="4">syndrome treatment (or gigantic capillary hemangio-</text>
<text top="747" left="457" width="334" height="19" font="4">mas) complicate the course of community-acquired </text>
<text top="766" left="457" width="150" height="19" font="4">pneumonia in children?</text>
<text top="784" left="487" width="303" height="19" font="4">3. Can the drugs used for pneumonia treatment </text>
<text top="803" left="457" width="329" height="19" font="4">worsen the course of the Kasabach-Merritt syndrome?</text>
<text top="822" left="487" width="300" height="19" font="4">Taking into consideration the fact that the vari-</text>
<text top="841" left="457" width="330" height="19" font="4">ous therapy methods of the Kasabach-Merritt syn-</text>
<text top="860" left="457" width="334" height="19" font="4">drome have shown ambiguous results, there are still </text>
<text top="878" left="457" width="334" height="19" font="4">no optimal treatment modalities. The reason is the </text>
<text top="897" left="457" width="334" height="19" font="4">rarity of the syndrome and the low effectiveness of </text>
<text top="916" left="457" width="334" height="19" font="4">the suggested treatment modality, the percentage of </text>
<text top="935" left="457" width="314" height="19" font="4">positive results of their usage does not exceed 50%</text>
<text top="936" left="771" width="12" height="11" font="7">3,6</text>
<text top="935" left="783" width="8" height="19" font="4">. </text>
<text top="954" left="457" width="329" height="19" font="4">Involution of the tumor and correction of life-threat-</text>
<text top="973" left="457" width="334" height="19" font="4">ening coagulopathy are the main objectives of the </text>
<text top="991" left="457" width="253" height="19" font="4">treatment of Kasabach-Merritt syndrome</text>
<text top="992" left="710" width="5" height="11" font="7">3</text>
<text top="991" left="715" width="75" height="19" font="4">. Currently, </text>
<text top="1010" left="457" width="334" height="19" font="4">different options of treatment are suggested, which </text>
<text top="1029" left="457" width="330" height="19" font="4">include pharmacological therapy, vascular embolisa-</text>
<text top="1048" left="457" width="334" height="19" font="4">tion, radiation therapy and surgical removal of the </text>
<text top="1067" left="457" width="39" height="19" font="4">tumor</text>
<text top="1067" left="496" width="52" height="11" font="7">3,6,7,12,18,19</text>
<text top="1067" left="548" width="4" height="19" font="4">.</text>
<text top="1085" left="487" width="303" height="19" font="4">Despite the radicality of the previously described </text>
<text top="1104" left="457" width="334" height="19" font="4">treatment modalities, the most commonly used are </text>
<text top="1123" left="457" width="335" height="19" font="4">drugs which facilitate the hemangioma involution </text>
<text top="1142" left="457" width="54" height="19" font="4">(Table 1)</text>
<text top="1142" left="511" width="9" height="11" font="7">20</text>
<text top="1142" left="520" width="4" height="19" font="4">.</text>
<text top="545" left="119" width="302" height="15" font="10"><b>Figure 2</b>. Petechiae and extensive intradermal hemor-</text>
<text top="562" left="132" width="276" height="15" font="9">rhages in a child with Kasabach-Merritt syndrom</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="11" size="13" family="Times" color="#231f20"/>
	<fontspec id="12" size="11" family="Times" color="#231f20"/>
	<fontspec id="13" size="5" family="Times" color="#231f20"/>
<text top="91" left="106" width="667" height="14" font="9">Features of the community–acquired pneumonia in a child with kasabach-merritt syndrome… – BOYARCHUK et al</text>
<text top="1182" left="106" width="143" height="14" font="9">388  /  vol. 54, no. 2</text>
<text top="587" left="136" width="305" height="19" font="4">Hormonotherapy with corticosteroids for the </text>
<text top="606" left="106" width="333" height="19" font="4">Kasabach-Merritt syndrome in children should be </text>
<text top="625" left="106" width="335" height="19" font="4">considered as a primary treatment method, if the </text>
<text top="644" left="106" width="179" height="19" font="4">surgery cannot be performed</text>
<text top="645" left="285" width="49" height="11" font="7">3,17,20,21,23</text>
<text top="644" left="335" width="105" height="19" font="4">. However, these </text>
<text top="663" left="106" width="333" height="19" font="4">drugs effectiveness, as indicated by most researchers, </text>
<text top="682" left="106" width="86" height="19" font="4">is ambiguous</text>
<text top="683" left="192" width="16" height="11" font="7">6,19</text>
<text top="682" left="209" width="227" height="19" font="4">. Additionally, after dose interrup-</text>
<text top="702" left="106" width="333" height="19" font="4">tion, a rapid tumor growth occurs, hence the need for </text>
<text top="721" left="106" width="333" height="19" font="4">repeated courses of treatment, with increased risk of </text>
<text top="740" left="106" width="67" height="19" font="4">side effects</text>
<text top="740" left="174" width="5" height="11" font="7">6</text>
<text top="740" left="178" width="261" height="19" font="4">. Corticosteroids accelerate the symptoms </text>
<text top="759" left="106" width="333" height="19" font="4">disappearance, reduce the incidence of relapse of the </text>
<text top="778" left="106" width="330" height="19" font="4">disease, can improve the parameters of alveolar-arte-</text>
<text top="797" left="106" width="333" height="19" font="4">rial oxygen transfer and reduce the need for artificial </text>
<text top="816" left="106" width="121" height="19" font="4">ventilation of lungs</text>
<text top="817" left="227" width="9" height="11" font="7">24</text>
<text top="816" left="237" width="4" height="19" font="4">.</text>
<text top="836" left="136" width="304" height="19" font="4">Interferon or propranolol can be used in case of </text>
<text top="855" left="106" width="329" height="19" font="4">hormonotherapy failure. Combined modality treat-</text>
<text top="874" left="106" width="333" height="19" font="4">ment using specified drug groups (steroids, IFN, </text>
<text top="893" left="106" width="317" height="19" font="4">and propranolol) is the most commonly suggested</text>
<text top="894" left="423" width="9" height="11" font="7">19</text>
<text top="893" left="432" width="8" height="19" font="4">. </text>
<text top="912" left="106" width="330" height="19" font="4">Currently, propranolol is a first-line drug in the gigan-</text>
<text top="931" left="106" width="333" height="19" font="4">tic hemangiomas treatment without Kasabach-Merritt </text>
<text top="950" left="106" width="335" height="19" font="4">syndrome. In our case, before hospitalization, the </text>
<text top="970" left="106" width="333" height="19" font="4">child received combined therapy with corticosteroids </text>
<text top="989" left="106" width="329" height="19" font="4">and propranolol, and according to information pro-</text>
<text top="1008" left="106" width="330" height="19" font="4">vided by mother and medical records, a positive clini-</text>
<text top="1027" left="106" width="333" height="19" font="4">cal effect was observed (hemangioma’s size reduction </text>
<text top="1046" left="106" width="329" height="19" font="4">and reduction of the hemorrhagic syndrome mani-</text>
<text top="1065" left="106" width="67" height="19" font="4">festations).</text>
<text top="1084" left="136" width="305" height="19" font="4">It should be noted that almost all drugs used </text>
<text top="1104" left="106" width="335" height="19" font="4">for the Kasabach-Merritt syndrome treatment can </text>
<text top="1123" left="106" width="329" height="19" font="4">increase the risk of pneumonia, by immune depres-</text>
<text top="1142" left="106" width="334" height="19" font="4">sion and opportunistic infection development. This </text>
<text top="587" left="457" width="330" height="19" font="4">particularly concerns the use of corticosteroids, vin-</text>
<text top="606" left="457" width="150" height="19" font="4">cristine, and interferon.</text>
<text top="625" left="487" width="306" height="19" font="4">Impaired coagulation correction is also an </text>
<text top="644" left="457" width="330" height="19" font="4">important treatment for the Kasabach-Merritt syn-</text>
<text top="663" left="457" width="329" height="19" font="4">drome. The lack of precise information on the eti-</text>
<text top="682" left="457" width="334" height="19" font="4">ology of coagulopathy has led to the application of </text>
<text top="702" left="457" width="329" height="19" font="4">both substitution therapy and drugs used for dis-</text>
<text top="721" left="457" width="333" height="19" font="4">seminated intravascular blood coagulation treatment </text>
<text top="740" left="457" width="330" height="19" font="4">(antiplatelet therapy, anticoagulants, fibrinolysis in-</text>
<text top="759" left="457" width="84" height="19" font="4">hibitors, etc.)</text>
<text top="760" left="541" width="9" height="11" font="7">14</text>
<text top="759" left="550" width="241" height="19" font="4">. Heparin and antiplatelet therapy in </text>
<text top="778" left="457" width="330" height="19" font="4">the Kasabach-Merritt syndrome treatment have prob-</text>
<text top="797" left="457" width="105" height="19" font="4">lematical success</text>
<text top="798" left="562" width="27" height="11" font="7">6,14,21</text>
<text top="797" left="589" width="198" height="19" font="4">. The best results have been ob-</text>
<text top="816" left="457" width="334" height="19" font="4">served with the usage of fibrinolysis inhibitors, such </text>
<text top="836" left="457" width="306" height="19" font="4">as tranexamic acid and ypsilon-aminocaproic acid</text>
<text top="836" left="763" width="20" height="11" font="7">14,21</text>
<text top="836" left="783" width="8" height="19" font="4">. </text>
<text top="855" left="457" width="335" height="19" font="4">In our case, -aminocaproic acid in particular was </text>
<text top="874" left="457" width="145" height="19" font="4">used for the treatment.</text>
<text top="893" left="487" width="304" height="19" font="4">As many researchers consider, the transfusion </text>
<text top="912" left="457" width="330" height="19" font="4">of plasma and platelets is the basis of the Kasabach-</text>
<text top="931" left="457" width="188" height="19" font="4">Merritt syndrome treatment</text>
<text top="932" left="646" width="9" height="11" font="7">25</text>
<text top="931" left="656" width="136" height="19" font="4">. Blood transfusion </text>
<text top="950" left="457" width="329" height="19" font="4">should be retained if there is no evidence of bleed-</text>
<text top="970" left="457" width="334" height="19" font="4">ing, since cytokines from the transfusive blood can </text>
<text top="989" left="457" width="333" height="19" font="4">aggravate the angiogenic process and lead to increase </text>
<text top="1008" left="457" width="132" height="19" font="4">in hemangioma’s size</text>
<text top="1008" left="589" width="9" height="11" font="7">21</text>
<text top="1008" left="598" width="4" height="19" font="4">.</text>
<text top="1027" left="487" width="300" height="19" font="4">Another important issue is the impact of medi-</text>
<text top="1046" left="457" width="329" height="19" font="4">cations used for the community-acquired pneumo-</text>
<text top="1065" left="457" width="334" height="19" font="4">nia treatment on the KMS course. The antibacterial </text>
<text top="1084" left="457" width="334" height="19" font="4">agents, anti-inflammatory therapy and expectorants </text>
<text top="1104" left="457" width="333" height="19" font="4">form the basis of the community-acquired pneumonia </text>
<text top="1123" left="457" width="62" height="19" font="4">treatment</text>
<text top="1123" left="520" width="9" height="11" font="7">26</text>
<text top="1123" left="529" width="262" height="19" font="4">. Antibiotics of different groups are one </text>
<text top="1142" left="457" width="334" height="19" font="4">of the main medications that can actively influence </text>
<text top="123" left="201" width="491" height="17" font="11"><b>Table 1. </b>The main drugs used for the treatment of Kasabach-Merritt syndrome.</text>
<text top="147" left="149" width="34" height="13" font="12"><i><b>Drugs</b></i></text>
<text top="147" left="299" width="139" height="13" font="12"><i><b>Expected positive impact</b></i></text>
<text top="147" left="617" width="63" height="13" font="12"><i><b>Side effects</b></i></text>
<text top="211" left="122" width="87" height="15" font="9">Glucocorticoids</text>
<text top="166" left="229" width="245" height="15" font="9">Mechanisms remain completely unclear, but </text>
<text top="181" left="229" width="253" height="15" font="9">apparently the effect is related to vasoconstric-</text>
<text top="196" left="229" width="269" height="15" font="9">tion, suppressing fibrinolysis (by suppressing the </text>
<text top="211" left="229" width="262" height="15" font="9">production of tissues of plasminogen activators </text>
<text top="226" left="229" width="259" height="15" font="9">and increasing in plasminogen activator inhibi-</text>
<text top="241" left="229" width="24" height="15" font="9">tors)</text>
<text top="241" left="254" width="4" height="9" font="13">8</text>
<text top="241" left="258" width="250" height="15" font="9">, prolonging platelet counts and angiogenesis </text>
<text top="256" left="229" width="45" height="15" font="9">disorder</text>
<text top="256" left="274" width="8" height="9" font="13">21</text>
<text top="173" left="515" width="244" height="15" font="9">Child’s growth and developmental disorders, </text>
<text top="188" left="515" width="266" height="15" font="9">reversible osteoporosis, increased sensitivity to in-</text>
<text top="203" left="515" width="37" height="15" font="9">fection</text>
<text top="204" left="552" width="8" height="9" font="13">21</text>
<text top="203" left="560" width="220" height="15" font="9">, edema, due to the sodium chloride and </text>
<text top="218" left="515" width="269" height="15" font="9">water delay in the body, increased blood pressure, </text>
<text top="233" left="515" width="246" height="15" font="9">petechia, ecchymosis, thrombosis, psychiatric </text>
<text top="248" left="515" width="237" height="15" font="9">disorders, Itsenko-Cushing’s syndrome, etc. </text>
<text top="249" left="752" width="8" height="9" font="13">22</text>
<text top="306" left="118" width="96" height="15" font="9">Interferon alfa-2b</text>
<text top="284" left="229" width="247" height="15" font="9">Inhibition of angiogenesis and proliferation, </text>
<text top="299" left="229" width="251" height="15" font="9">inhibition of expression of the main factor of </text>
<text top="314" left="229" width="276" height="15" font="9">fibroblasts growth (bFGF) and angiogenic protein </text>
<text top="329" left="229" width="91" height="15" font="9">in hemangiomas</text>
<text top="329" left="320" width="8" height="9" font="13">21</text>
<text top="329" left="327" width="3" height="15" font="9">.</text>
<text top="276" left="515" width="241" height="15" font="9">Fever, weakness and fatigue, increased liver </text>
<text top="291" left="515" width="265" height="15" font="9">enzymes, nausea, renal failure, neutropenia and </text>
<text top="306" left="515" width="255" height="15" font="9">anemia, hypothyroidism, bone marrow depres-</text>
<text top="321" left="515" width="268" height="15" font="9">sion, myalgia, ataxia, paresthesia, numbness, eye </text>
<text top="336" left="515" width="244" height="15" font="9">paralysis, retinopathy, spasmodic dislocation</text>
<text top="337" left="759" width="8" height="9" font="13">21</text>
<text top="336" left="767" width="3" height="15" font="9">.</text>
<text top="394" left="135" width="61" height="15" font="9">Vincristine</text>
<text top="387" left="229" width="267" height="15" font="9">Increase in number of platelets and a significant </text>
<text top="402" left="229" width="212" height="15" font="9">reduction in size of the vascular tumor</text>
<text top="402" left="441" width="4" height="9" font="13">6</text>
<text top="402" left="445" width="3" height="15" font="9">.</text>
<text top="357" left="515" width="263" height="15" font="9">Reversible alopecia, nausea, vomiting, autonom-</text>
<text top="372" left="515" width="262" height="15" font="9">ic neuropathy, peripheral paresthesia, jaundice, </text>
<text top="387" left="515" width="240" height="15" font="9">ataxia and hyponatremia due to inappropri-</text>
<text top="402" left="515" width="239" height="15" font="9">ate hypersecretion of antidiuretic hormone </text>
<text top="417" left="515" width="54" height="15" font="9">syndrome</text>
<text top="417" left="569" width="4" height="9" font="13">3</text>
<text top="417" left="573" width="185" height="15" font="9">, abdominal pain, irritability and </text>
<text top="432" left="515" width="211" height="15" font="9">temporary loss of deep tendon reflexes</text>
<text top="432" left="727" width="4" height="9" font="13">6</text>
<text top="432" left="731" width="3" height="15" font="9">.</text>
<text top="482" left="129" width="76" height="15" font="9">Beta-blockers </text>
<text top="497" left="129" width="72" height="15" font="9">(propranolol)</text>
<text top="452" left="229" width="254" height="15" font="9">Stop in growth and boost in the involution of </text>
<text top="467" left="229" width="252" height="15" font="9">hemangioma by vasoconstriction, decrease in </text>
<text top="482" left="229" width="267" height="15" font="9">expression of vascular endothelial growth factor </text>
<text top="497" left="229" width="271" height="15" font="9">(VEGF) and genes, the main factor of fibroblasts </text>
<text top="512" left="229" width="229" height="15" font="9">growth (bFGF) and initiation of capillary </text>
<text top="527" left="229" width="144" height="15" font="9">endothelial cells apoptosis</text>
<text top="528" left="374" width="4" height="9" font="13">3</text>
<text top="475" left="515" width="250" height="15" font="9">Hypotension, bradycardia, hypoglycemia and </text>
<text top="490" left="515" width="232" height="15" font="9">bronchospasm, heart failure, neurological </text>
<text top="505" left="515" width="50" height="15" font="9">disorders</text>
<text top="505" left="565" width="4" height="9" font="13">3</text>
<text top="505" left="569" width="3" height="15" font="9">.</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="14" size="11" family="Times" color="#231f20"/>
<text top="91" left="552" width="235" height="14" font="9">Archives of the Balkan Medical Union</text>
<text top="1182" left="661" width="42" height="14" font="9">June </text>
<text top="1182" left="693" width="94" height="14" font="9">2019 / 389</text>
<text top="126" left="106" width="317" height="19" font="4">coagulation, and in particular platelet hemostasis</text>
<text top="127" left="423" width="9" height="11" font="7">27</text>
<text top="126" left="432" width="8" height="19" font="4">. </text>
<text top="145" left="106" width="330" height="19" font="4">Thus, antibiotics of the aminoglycoside structure in-</text>
<text top="164" left="106" width="172" height="19" font="4">crease the platelet adhesion</text>
<text top="165" left="278" width="9" height="11" font="7">28</text>
<text top="164" left="288" width="4" height="19" font="4">.</text>
<text top="184" left="136" width="305" height="19" font="4">The penicillin suppresses platelet aggregation </text>
<text top="203" left="106" width="333" height="19" font="4">and reaction of biologically active substances release, </text>
<text top="222" left="106" width="330" height="19" font="4">blocking the ability of platelets to convert the arachi-</text>
<text top="241" left="106" width="333" height="19" font="4">donic acid into thromboxanes. Besides, it arrests 2 </text>
<text top="260" left="106" width="333" height="19" font="4">adrenoreceptors that causes the loss of affinity for </text>
<text top="279" left="106" width="333" height="19" font="4">thromboxane A2 and prostaglandin H2, and leads to </text>
<text top="298" left="106" width="329" height="19" font="4">an ionized calcium concentration decrease in plate-</text>
<text top="317" left="106" width="333" height="19" font="4">lets. These effects explain the irreversible inhibition of </text>
<text top="337" left="106" width="317" height="19" font="4">platelet functions in vitro and in vivo experiments</text>
<text top="337" left="423" width="9" height="11" font="7">29</text>
<text top="337" left="432" width="8" height="19" font="4">. </text>
<text top="356" left="106" width="333" height="19" font="4">The cephalosporins disrupt platelet functions, as they </text>
<text top="375" left="106" width="329" height="19" font="4">can affect the platelet aggregation, inhibiting the ac-</text>
<text top="394" left="106" width="271" height="19" font="4">tion of aggregation agonists (ADP, collagen)</text>
<text top="395" left="377" width="21" height="11" font="7">30,31</text>
<text top="394" left="398" width="4" height="19" font="4">.</text>
<text top="413" left="136" width="305" height="19" font="4">There are publications that report the lack of </text>
<text top="432" left="106" width="329" height="19" font="4">semi-synthetic -lactam antibiotics effect on hemo-</text>
<text top="451" left="106" width="34" height="19" font="4">stasis</text>
<text top="452" left="141" width="22" height="11" font="7">32,33</text>
<text top="451" left="163" width="279" height="19" font="4">. Taking into consideration this fact, we </text>
<text top="470" left="106" width="333" height="19" font="4">chose the antibiotic amoxicillin in combination with </text>
<text top="490" left="106" width="334" height="19" font="4">clavulanic acid, as an agent with the least effect on </text>
<text top="509" left="106" width="333" height="19" font="4">coagulation, for the community-acquired pneumonia </text>
<text top="528" left="106" width="156" height="19" font="4">treatment in our patient.</text>
<text top="568" left="106" width="12" height="18" font="1">C</text>
<text top="572" left="118" width="77" height="13" font="0">ONCLUSIONS</text>
<text top="604" left="136" width="300" height="19" font="4">The Kasabach-Merritt syndrome is a severe dis-</text>
<text top="623" left="106" width="329" height="19" font="4">ease that can lead to severe complications and sig-</text>
<text top="642" left="106" width="333" height="19" font="4">nificant deterioration of the course of other diseases, </text>
<text top="661" left="106" width="333" height="19" font="4">such as community-acquired pneumonia in children. </text>
<text top="680" left="106" width="329" height="19" font="4">This occurs due to coagulation disorders that con-</text>
<text top="699" left="106" width="335" height="19" font="4">tribute to the development of severe hemorrhagic </text>
<text top="718" left="106" width="334" height="19" font="4">complications. Such combination of diseases should </text>
<text top="737" left="106" width="329" height="19" font="4">be treated considering the drugs effects on both he-</text>
<text top="757" left="106" width="335" height="19" font="4">mostasis system and progression of hemangioma’s </text>
<text top="776" left="106" width="48" height="19" font="4">growth.</text>
<text top="837" left="106" width="267" height="15" font="3">Compliance with Ethics Requirements:</text>
<text top="852" left="136" width="304" height="19" font="8"><i>„The authors declare no conflict of interest regarding </i></text>
<text top="871" left="106" width="65" height="19" font="8"><i>this article“</i></text>
<text top="890" left="136" width="300" height="19" font="8"><i>„The authors declare that all the procedures and ex-</i></text>
<text top="909" left="106" width="334" height="19" font="8"><i>periments of this study respect the ethical standards in the </i></text>
<text top="928" left="106" width="334" height="19" font="8"><i>Helsinki Declaration of 1975, as revised in 2008(5), as </i></text>
<text top="948" left="106" width="334" height="19" font="8"><i>well as the national law. Informed consent was obtained </i></text>
<text top="967" left="106" width="219" height="19" font="8"><i>from the patient included in the study“</i></text>
<text top="986" left="136" width="158" height="19" font="8"><i>„No funding for this study “</i></text>
<text top="1045" left="106" width="12" height="18" font="1">R</text>
<text top="1049" left="118" width="71" height="13" font="0">EFERENCES</text>
<text top="1080" left="106" width="334" height="15" font="9">1.  North PE. Pediatric vascular tumors and malformations. </text>
<text top="1096" left="128" width="247" height="15" font="9">Surgical Pathology Clinics, 2010);3(3):455–494.</text>
<text top="1112" left="106" width="329" height="15" font="9">2.  Kollipara R, Dinneen L, Rentas KE, et al. Current classi-</text>
<text top="1128" left="128" width="312" height="15" font="9">fication and terminology of pediatric vascular anomalies. </text>
<text top="1144" left="128" width="291" height="15" font="14"><i>American Journal of Roentgenology</i>. 2013;201(5):1124-1135.</text>
<text top="126" left="457" width="332" height="15" font="9">3.  Arunachalam P, Ravi Kumar VR, Divya S. Kasabach-Merritt </text>
<text top="142" left="478" width="312" height="15" font="9">syndrome with large cutaneous vascular tumors. <i>J Indian </i></text>
<text top="158" left="478" width="180" height="15" font="14"><i>Assoc Pediatr Surg</i>. 2012;17(1);33-36.</text>
<text top="175" left="457" width="333" height="15" font="9">4.  Habif TP. Vascular tumors and malformations, 5th ed. St. </text>
<text top="191" left="478" width="182" height="15" font="9">Louis: Mosby Elsevier, 2009; p. 23.</text>
<text top="207" left="457" width="333" height="15" font="9">5.  Kwok-Williams  M,  Perez  Z,  Squire  R,  Glaser  A,  Bew  S, </text>
<text top="223" left="478" width="308" height="15" font="9">Taylor R. Radiotherapy for life-threatening mediastinal hae-</text>
<text top="239" left="478" width="312" height="15" font="9">mangioma with Kasabach-Merritt syndrome. <i>Pediatr Blood </i></text>
<text top="255" left="478" width="127" height="15" font="14"><i>Cancer</i>. 2007,49:739-744.</text>
<text top="272" left="457" width="171" height="15" font="9">6.  Oksiuta M, Matuszczak E, D</text>
<text top="272" left="628" width="5" height="17" font="0">ę</text>
<text top="272" left="634" width="156" height="15" font="9">bek W, Dzienis-Koronkiewicz </text>
<text top="288" left="478" width="311" height="15" font="9">E, Hermanowicz A. Successful exclusive propranolol therapy </text>
<text top="304" left="478" width="308" height="15" font="9">in an infant with life-threatening Kasabach–Merritt syn-</text>
<text top="320" left="478" width="214" height="15" font="9">drome<i>. J Pediatr Surg</i>. 2013;1(8); 200–202.</text>
<text top="336" left="457" width="329" height="15" font="9">7.  Wang P, Zhou W, Tao L, Zhao N, Chen X-W. Clinical analy-</text>
<text top="352" left="478" width="311" height="15" font="9">sis  of  Kasabach-Merritt  syndrome  in  17  neonates.  <i>BMC </i></text>
<text top="369" left="478" width="118" height="15" font="14"><i>Pediatrics</i>. 2014;14: 146</text>
<text top="385" left="457" width="334" height="15" font="9">8.  Osman NM. Kasabach–Merritt syndrome: a case report. </text>
<text top="401" left="478" width="181" height="15" font="14"><i>Sudan J Paediatr.</i> 2013;13(1): 49–52.</text>
<text top="417" left="457" width="334" height="15" font="9">9.  Dhandore PD, Hombalkar NN, Pancholi CK. Kasabach </text>
<text top="433" left="478" width="311" height="15" font="9">Merritt syndrome: is there a role of surgery? <i>J Clin Neonatol.</i> </text>
<text top="449" left="478" width="71" height="15" font="9">2016;5:58-60.</text>
<text top="466" left="457" width="334" height="15" font="9">10. Maguiness S, Guenther L. Kasabach-Merritt syndrome. </text>
<text top="482" left="478" width="290" height="15" font="14"><i>Journal of Cutaneous Medicine &amp; Surgery.</i> 2002;6:335–339.</text>
<text top="498" left="457" width="329" height="15" font="9">11.  Jain TP, Sharma R, Gupta R. Subcutaneous hemangioma-</text>
<text top="514" left="478" width="311" height="15" font="9">tosis causing Kasabach-Merritt syndrome – MRI features. <i>J </i></text>
<text top="530" left="478" width="184" height="15" font="14"><i>Radiol Imaging.</i> 2008;18(4):295–297.</text>
<text top="546" left="457" width="329" height="15" font="9">12.  Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt phenom-</text>
<text top="563" left="478" width="311" height="15" font="9">enon: classic presentation and management options. <i>Clinical </i></text>
<text top="579" left="478" width="230" height="15" font="14"><i>Medicine Insights: Blood Disorders</i>. 2017;10:1-5.</text>
<text top="595" left="457" width="333" height="15" font="9">13.  Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function </text>
<text top="611" left="478" width="258" height="15" font="9">and dysfunction. <i>Circulation</i>. 2007;115:1285-1295.</text>
<text top="627" left="457" width="335" height="15" font="9">14. Larsen EC, Zinkham WH, Eggleston JC, Zitelli BJ. </text>
<text top="643" left="478" width="313" height="15" font="9">Kasabach-Merritt syndrome: therapeutic considerations. </text>
<text top="660" left="478" width="153" height="15" font="14"><i>Pediatrics.</i> 1987;79(6):971-980.</text>
<text top="676" left="457" width="335" height="15" font="9">15. Hall GW. Kasabach-Merritt syndrome: pathogenesis </text>
<text top="692" left="478" width="311" height="15" font="9">and management: review. <i>British Journal of Haematology.</i> </text>
<text top="708" left="478" width="94" height="15" font="9">2001;112;851-862.</text>
<text top="724" left="457" width="333" height="15" font="9">16.  Kelly M. Kasabach-Merritt phenomenon. <i>Pediatr Clin N Am.</i> </text>
<text top="740" left="478" width="103" height="15" font="9">2010;57:1085–1089.</text>
<text top="757" left="457" width="333" height="15" font="9">17.  Butorina AV, Shafranov VV. Rol gormonoterapii v lechenii </text>
<text top="773" left="478" width="311" height="15" font="9">sindroma Kazabakha-Merrita u detey. <i>Lechashchiy vrach</i>. </text>
<text top="789" left="478" width="131" height="15" font="9">1999;8: 28-30. [Russian]  </text>
<text top="805" left="457" width="333" height="15" font="9">18.  Abass K, Saad H, Kherala M, Abd-Elsayed AA. Successful </text>
<text top="821" left="478" width="312" height="15" font="9">treatment of Kasabach-Merritt syndrome with vincristine </text>
<text top="837" left="478" width="311" height="15" font="9">and surgery: a case report and review of literature. <i>Cases </i></text>
<text top="854" left="478" width="58" height="15" font="14"><i>J</i>. 2008;1:9.</text>
<text top="870" left="457" width="329" height="15" font="9">19.  Kim JA, Choi YB, Yi ES, et al. Excellent outcome of medi-</text>
<text top="886" left="478" width="311" height="15" font="9">cal treatment for Kasabach-Merritt syndrome: a single-center </text>
<text top="902" left="478" width="221" height="15" font="9">experience. <i>Blood Res</i>. 2016;51(4);256–260.</text>
<text top="918" left="457" width="332" height="15" font="9">20.  Moura R, Sobreira ML. Kasabach-Merritt syndrome: clinical </text>
<text top="934" left="478" width="279" height="15" font="9">vs. surgical treatment. <i>J Vasc Bras. </i>2014; 13(4):330-335</text>
<text top="950" left="457" width="334" height="15" font="9">21.  Yadav D, Maheshwari A, Aneja S, Seth A, Chandra J. </text>
<text top="967" left="478" width="313" height="15" font="9">Neonatal Kasabach-Merritt phenomenon. <i>Indian J Med </i></text>
<text top="983" left="478" width="186" height="15" font="14"><i>Paediatr Oncol</i>. 2011;32(4): 238–241.</text>
<text top="999" left="457" width="334" height="15" font="9">22. Moghadam-Kia S, Werth VP. Prevention and treatment </text>
<text top="1015" left="478" width="311" height="15" font="9">of systemic glucocorticoid side effects. <i>Int J Dermatol.</i> </text>
<text top="1031" left="478" width="94" height="15" font="9">2010;49(3):239-48</text>
<text top="1047" left="457" width="333" height="15" font="9">23.  Jiang RS, Hu R. Successful treatment of Kasabach-Merritt </text>
<text top="1064" left="478" width="312" height="15" font="9">syndrome arising from kaposiform hemangioendothelioma </text>
<text top="1080" left="478" width="312" height="15" font="9">by systemic corticosteroid therapy and surgery. <i>Int J Clin </i></text>
<text top="1096" left="478" width="124" height="15" font="14"><i>Oncol</i>. 2012;17:512–516.</text>
<text top="1112" left="457" width="330" height="15" font="9">24.  Chen  Y,  Li  K,  Pu  H,  Wu  T.  Corticosteroids  for  pneu-</text>
<text top="1128" left="478" width="311" height="15" font="9">moniae. Cochraine Database of <i>Systematic Reviews.</i> </text>
<text top="1144" left="478" width="98" height="15" font="9">2011;3:CD007729.</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1262" width="892">
<text top="91" left="106" width="667" height="14" font="9">Features of the community–acquired pneumonia in a child with kasabach-merritt syndrome… – BOYARCHUK et al</text>
<text top="1182" left="106" width="143" height="14" font="9">390  /  vol. 54, no. 2</text>
<text top="126" left="106" width="335" height="15" font="9">25. Henley J D, Danielson CFM, Rothenberger SS, et al. </text>
<text top="142" left="128" width="311" height="15" font="9">Kasabach-Merritt syndrome with profound platelet support. </text>
<text top="158" left="128" width="138" height="15" font="14"><i>AJCP</i>. 1993;99(5);628-630.</text>
<text top="173" left="106" width="340" height="15" font="9">26. S t u c k e y - S c h r o c k   K ,   H a y e s   BL ,   G e or g   C M . </text>
<text top="189" left="128" width="311" height="15" font="9">Community-acquired pneumonia in children. <i>American </i></text>
<text top="205" left="128" width="188" height="15" font="14"><i>Family Physician</i>. 2012;86(7):661-667.</text>
<text top="221" left="106" width="330" height="15" font="9">27. Hicks, MJ, Flaitz CM. The role of antibiotics in plate-</text>
<text top="236" left="128" width="312" height="15" font="9">let dysfunction and coagulopathy. <i>International Journal of </i></text>
<text top="252" left="128" width="204" height="15" font="14"><i>Antimicrobial Agents</i>. 1993;2(3):129–149.</text>
<text top="268" left="106" width="330" height="15" font="9">28. Kotte W, Scharfe V. Drug effect on the rotation thromboe-</text>
<text top="284" left="128" width="312" height="15" font="9">lastogram in newborn infants. <i>Folia Haematol Int Mag Klin </i></text>
<text top="299" left="128" width="194" height="15" font="14"><i>Morphol Blutforsch</i>. 1983;110(1):86-93.</text>
<text top="315" left="106" width="333" height="15" font="9">29.  Burroughs SF, Johnson GJ. Beta-lactam antibiotic-induced </text>
<text top="331" left="128" width="312" height="15" font="9">platelet dysfunction: evidence for irreversible inhibition of </text>
<text top="126" left="478" width="308" height="15" font="9">platelet activation in vitro and in vivo after prolonged expo-</text>
<text top="142" left="478" width="229" height="15" font="9">sure to penicillin. <i>Blood.</i> 1990;75;7; 1473-80.</text>
<text top="158" left="457" width="329" height="15" font="9">30.  Cazzola M, Matera MG, Santangelo G. Effects of some ceph-</text>
<text top="173" left="478" width="311" height="15" font="9">alosporins and teicoplanin on platelet aggregation. <i>Int J Clin </i></text>
<text top="189" left="478" width="165" height="15" font="14"><i>Pharmacol Res</i>. 1993;13(2):69-73.</text>
<text top="205" left="457" width="329" height="15" font="9">31.  Kariyazono H, Nakamura K, Shinkawa T. Inhibitory ef-</text>
<text top="221" left="478" width="311" height="15" font="9">fects of antibiotics on platelet aggregation in vitro. <i>Hum Exp </i></text>
<text top="236" left="478" width="148" height="15" font="14"><i>Toxicol</i>. 1997;16(11);662-666.</text>
<text top="252" left="457" width="332" height="15" font="9">32.  Frese A, Rinke D, Künnecke M. Platelet aggregation during </text>
<text top="268" left="478" width="311" height="15" font="9">abdominal surgery in an experimental pig model: the effects </text>
<text top="284" left="478" width="312" height="15" font="9">of presurgical antibiotic protocols and volume replacement </text>
<text top="299" left="478" width="299" height="15" font="9">with hydroxyethyl starch. <i>Thromb Res</i>. 2000;97(3):143-151.</text>
<text top="315" left="457" width="332" height="15" font="9">33.  Sattler FR, Weitekamp MR, Seyegh A, Ballard JO. Impaired </text>
<text top="331" left="478" width="311" height="15" font="9">hemostasis caused by beta-lactam antibiotics.<i> The American </i></text>
<text top="347" left="478" width="190" height="15" font="14"><i>Journal of Surgery. </i>1988;155(5):30–39.</text>
</page>
</pdf2xml>
